Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellar Study: Steroid Injection Plus Oral Steroid to Prevent Esophageal Stricture After ESD
jRCTs031220557Recruiting
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of triamcinolone and prednisolone in esophageal cancer. Primary endpoint: Esophageal non-stenosis rate up to 12 weeks after ESD. Started Jan 2023; status: recruiting.
02
Drugs
triamcinoloneprednisolone
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs031220557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220557.